Humankind Investments LLC Acquires 15,319 Shares of Pfizer Inc. (NYSE:PFE)

Humankind Investments LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 98,972 shares of the biopharmaceutical company's stock after purchasing an additional 15,319 shares during the period. Pfizer comprises 0.7% of Humankind Investments LLC's holdings, making the stock its 23rd largest holding. Humankind Investments LLC's holdings in Pfizer were worth $2,626,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PFE. Gotham Asset Management LLC increased its stake in Pfizer by 333.4% during the 4th quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company's stock worth $3,742,000 after acquiring an additional 108,494 shares during the period. Focus Partners Wealth raised its stake in Pfizer by 65.6% in the fourth quarter. Focus Partners Wealth now owns 1,311,901 shares of the biopharmaceutical company's stock valued at $35,077,000 after purchasing an additional 519,522 shares in the last quarter. Forefront Analytics LLC lifted its position in Pfizer by 4.3% during the fourth quarter. Forefront Analytics LLC now owns 14,903 shares of the biopharmaceutical company's stock worth $395,000 after purchasing an additional 609 shares during the period. Ensign Peak Advisors Inc grew its stake in Pfizer by 27.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 6,445,011 shares of the biopharmaceutical company's stock worth $170,986,000 after buying an additional 1,383,305 shares in the last quarter. Finally, Ethic Inc. increased its holdings in Pfizer by 40.4% in the 4th quarter. Ethic Inc. now owns 449,474 shares of the biopharmaceutical company's stock valued at $11,925,000 after buying an additional 129,381 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Down 3.0 %

Shares of Pfizer stock opened at $22.28 on Friday. The stock has a fifty day moving average price of $24.02 and a 200-day moving average price of $25.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $126.67 billion, a PE ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm posted $0.82 earnings per share. The company's revenue for the quarter was down 7.8% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.72%. Pfizer's payout ratio is presently 124.64%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.